|
Amgen has announced positive results from a clinical study evaluating the safety and efficacy of biosimilar candidate, ABP 501, compared with adalimumab (Humira, Abbott Laboratories) in patients with moderate-to-severe rheumatoid arthritis. » Details on this phase 3 study
|
Continuing Education
This month and next month pharmacists will be able to learn about the latest developments in diabetes treatment and management. Pharmacists can earn up to 4 hours of CPE credit with two monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.
The goal of this month's activity is to discuss new and emerging medications for the treatment of diabetes.
Read/print the article: Click here
Take the test: Click here to log in with the Session Code 15DT15-WKX27.
Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/
|
|
|
Like
Tweet
